Salute e Benessere

BioArctic's global license agreement with Bristol Myers Squibb for…

BioArctic's PyroGlu-Aβ antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aβ are highly prone to aggregate, leading to the formation of harmful aggregates which cause debilitating cognitive and other symptoms in Alzheimer's disease. The agreement includes both the BAN1503 and BAN2803 antibodies. BAN2803 includes BioArctic's BrainTransporter™ technology. BioArctic's PyroGlu-Aβ antibody program consists...
PR Newswire
20/02/2025

NaviFUS Corp. Advances Non-Invasive Precision Medicine for Brain Disorders with…

The NaviFUS system uses transcranial focused ultrasound and therapeutic guidance tracking for drug delivery and neuromodulation, offering new hope for patients with brain cancer and drug-resistant epilepsy. The NaviFUS system uses transcranial focused ultrasound and therapeutic guidance tracking for drug delivery and neuromodulation, offering new hope for patients with brain cancer and drug-resistant epilepsy. Strong Industry Backing and Global Collaborations NaviFUS has secured support...
PR Newswire
20/02/2025

LG REVEALS NEW "SKS" BRANDING FOR ITS LUXURY SIGNATURE KITCHEN SUITE BUILT-IN…

The transformation reflects the brand's refined aesthetic, modern positioning and steadfast commitment to sophisticated design and advanced innovation. The new "SKS" is designed to resonate more strongly with customers worldwide while maintaining the brand's essence. This rebranding underscores SKS's leadership in the luxury built-in appliances. The transformation reflects the brand's refined aesthetic, modern positioning and steadfast commitment to sophisticated design and advanced…
PR Newswire
20/02/2025

Spinal Cord Injury Drug Treatment Market is Predicted to Reach New Heights with…

In 2023, there were an estimated959K total diagnosed prevalent cases of SCI across the 7MM, with the number expected to rise by 2034, as per DelveInsight analysis. According to estimates, there were approximately 19K acute (incidence) cases of SCI across the US in 2023, with the number expected to rise by 2034. In 2023, there were an estimated959K total diagnosed prevalent cases of SCI across the 7MM, with the number expected to rise by 2034, as per DelveInsight analysis. According to...
PR Newswire
19/02/2025

Casino Group: Quatrim redemption

Confirmation of a repayment to Quatrim secured bondholders Paris, 19 February 2025Groupe Casino announces that it has repaid on February 18, 2025, €30.0m of the secured debt carried by its subsidiary Quatrim, including €28.5m of principal and €1.5m of accrued interest (including € 0.5m of PIK interests for the period between March 27, 2024 and October 5, 2024 and €1.0m of accrued interests for the period between October 6, 2024 and February 17, 2025).Following the transaction, the...
Nasdaq GlobeNewswire
19/02/2025

Carbon Unveils FP3D Resin, Introducing Proven Dual-Cure Technology to Dental…

FP3D challenges what was thought possible with 3D-printed dental resins. Carbon's first dental resin leveraging its proprietary dual-cure chemistry, a technology that has driven innovation across multiple industries. FP3D was engineered to push the boundaries of durability, flexibility, and strength and designed to achieve properties similar to some traditionally produced, polymer-based flexible partial denture materials. Expected to launch in late 2025, pending FDA clearance, FP3D may redefine…
PR Newswire
19/02/2025

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL…

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL SpeakersHalle (Saale) / Munich, Germany, February 19, 2025– Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual R&D update with KOL (Key Opinion Leader)...
Nasdaq GlobeNewswire
19/02/2025

Investors Eye Biotech Sector as Cancer Therapy Market Surges

The article continued: The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care (CITEC) has launched a global initiative focused on accelerating next-generation cancer detection technologies. With demand for advanced oncology solutions increasing, industry projections suggest significant market expansion, as DelveInsight Business Research forecasts a 9.12% compound annual growth rate (CAGR)—pushing the global cancer therapy market to an estimated $285.96…
PR Newswire
19/02/2025

KFSHRC Performs Groundbreaking Procedure to Save Child's Leg from Amputation

RIYADH, Saudi Arabia, Feb.19, 2025(GLOBE NEWSWIRE) -- In a pioneering medical achievement, King Faisal Specialist Hospital & Research Centre (KFSHRC) successfully reconstructed the lower limb of an 8-year-old child following the removal of a malignant bone tumor, preventing the need for amputation and enabling the child to regain normal walking ability. This innovative approach marks a significant advancement in pediatric orthopedic oncology in the Middle East, offering hope to...
Nasdaq GlobeNewswire
19/02/2025

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care…

Media ReleaseCOPENHAGEN, Denmark; February 19, 2025 Genmab A/S (Nasdaq:GMAB)announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45 th Annual TD Cowen Health Care Conferencein Boston , Massachusettsat 1:50 PMEST (7:50 PM CET)on March 3 , 2025 . A webcast of the fireside chat will be available on...
Nasdaq GlobeNewswire
19/02/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 19 February 2025 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 18 February...
Nasdaq GlobeNewswire
19/02/2025

BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global…

"As BluMaiden enters the exciting phase of scaling operations in the US, advancing its first targets to pre-clinical models, and expanding commercial partnerships to accelerate the development of more effective therapeutics, we are pleased to welcome Terry and Damian in their new roles. Their breadth of experience in global drug discovery, clinical development leadership, and commercial strategy will bring important insights to the team," commented Michael Tillman, Chairman of…
PR Newswire
19/02/2025

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs…

Ona has appointed Dr. Aleix Prat, an internationally recognized leader in precision oncology with an outstanding track record in cancer research, biomarker development, and clinical trials, as Chair of the Advisory Board. In collaboration with Ona's Advisor, Dr. Roger Gomis, he has been instrumental in identifying the target of ONA-255 and functionally validating it, working alongside the expert team at Ona. Their combined efforts have generated critical preclinical data to support the clinical…
PR Newswire
19/02/2025

Photocure ASA: Results for the fourth quarter of 2024

Photocure reported total group revenues of NOK 141.7 million in the fourth quarter of 2024 (NOK 142.5 million), and EBITDA* of NOK 8.5 million (Q4 2023: NOK 29.9 million), while Hexvix/Cysview revenues grew to NOK 128.6 million in the quarter (NOK 114.2 million). The EBIT was NOK 1.2 million (NOK 22.5 million) and the cash balance at the end of the period was NOK 293.8 million (NOK 259.5 million). Photocure reported total group revenues ofNOK 141.7 millionin the fourth quarter of 2024 ( NOK...
PR Newswire
19/02/2025

Frontier Scientific Solutions' Free Trade Zone Advantage Becomes Critical Amid…

"Foreign Trade Zones are more critical now than ever," said Steve Uebele, Chief Executive Officer of Frontier Scientific Solutions. "With increased tariffs on pharmaceutical raw materials, components, and finished products, our Free Trade Zone designation ensures that companies can continue to move high-value, temperature-sensitive goods efficiently while reducing unnecessary financial burdens." "Foreign Trade Zones are more critical now than ever," saidSteve…
PR Newswire
19/02/2025

Over 30,000 patients treated with Versius

Over 30,000 patients treated with Versius Versius—the second most utilised soft tissue surgical robot in the world i —has now been used in over 30,000 surgical cases globally across a broad range of specialties including urology, general surgery, gynaecology and thoracic surgeryOver 70% of hospitals that have introduced Versius are using it across two or more specialties iidue to the versatility and adaptability of the systemLaunch of significant enhancements to Versius Plus...
Nasdaq GlobeNewswire
19/02/2025

Press Release: Sanofi and CD&R sign Opella share purchase agreement

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025 .Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in Opella to CD&R. Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder.The terms of the transaction remain...
Nasdaq GlobeNewswire
19/02/2025

Philips proposes new Supervisory Board appointments and reappointments, and…

Mr David Pyott to retire from Philips' Supervisory Board after his third consecutive term.Mr Bob White proposed as new member of the Supervisory Board.Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board.Mr Marnix van Ginneken proposed for reappointment as member of Philips' Board of Management. February 19, 2025Amsterdam, the Netherlands – Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today...
Nasdaq GlobeNewswire
19/02/2025

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle…

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates Mont-Saint-Guibert, Belgium – February 19, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the...
Nasdaq GlobeNewswire
19/02/2025

Philips delivers growth, improved profitability, and strong cash flow in Q4 and…

Full Year and Q4 Group performance highlightsSales of EUR 18.0 billion in 2024, comparable sales growth 1%; EUR 5.0 billion in Q4, comparable sales growth 1%, despite double-digit decline in ChinaComparable order intake increased 1% in 2024; up 2% in Q4, despite double-digit decline in ChinaIncome from operations was EUR 529 million in 2024; EUR 199 million in Q4Adjusted EBITA margin increased 90 basis points to 11.5% of sales in 2024; up 60 basis points to 13.5% in Q4Net...
Nasdaq GlobeNewswire
19/02/2025

LG SHOWCASES WIDE SELECTION OF LAUNDRY SOLUTIONS INCLUDING HEAT PUMP WASHER AND…

LG's washer and dryer, powered by LG's energy-efficient dual inverter heat pump, will be displayed in the Zero Venting zone of LG's booth at KBIS. Featuring an innovative ventless design, these laundry solutions are easier to install than conventional vented models and optimize space utilization, making them easier to install. In addition, LG's laundry solutions employ Artificial Intelligence Direct Drive™ (AI DD™) technology that offers sophisticated clothing care with a simpler user…
PR Newswire
19/02/2025

BioVaxys Announces Debt Settlement Agreement, Extension of Private Placement…

All securities proposed to be issued in connection with the Debt Settlement will be subject to a statutory hold period of at least four months from the date of issuance in accordance with applicable securities legislation. The closing of the Debt Settlement is conditional upon the receipt of all applicable corporate and regulatory approvals, including the acceptance of the Canadian Securities Exchange. All securities proposed to be issued in connection with the Debt Settlement will be subject...
PR Newswire
19/02/2025

Global Transmucosal Drugs Market to Reach ~USD 28 Billion by 2032 | DelveInsight

Key Takeaways from the Transmucosal Drugs Market Report Key Takeaways from the Transmucosal Drugs Market Report To read more about the latest highlights related to the transmucosal drugs market, get a snapshot of the key highlights entailed in theGlobal Transmucosal Drugs Market Report Transmucosal Drugs Overview Transmucosal drugs are a category of medications designed to be absorbed through mucous membranes, such as those found in the mouth, nasal passages, or gastrointestinal tract...
PR Newswire
18/02/2025

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented…

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations .Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About the Teva and Sanofi Collaboration Teva and Sanofi are collaborating to co-develop and co-commercialize Teva's duvakitug...
Nasdaq GlobeNewswire
18/02/2025
Altri  Comunicati